RECOVERY & TISSUE REPAIR / FAQ
Questions, Answered From the Record
Plain-English, citation-anchored answers to the questions readers most commonly bring to these six repair peptides and blends.
What does BPC-157 do in the body?
In animal models, BPC-157 acts as a cytoprotective and regenerative peptide. Its healing effects trace most consistently to angiogenesis — encouraging new blood-vessel growth into injured tissue by making endothelial cells more responsive to the VEGFR2 vessel-growth signal [4]. It has accelerated healing in rat models of gastric ulcers [5], transected Achilles tendon [6], and is described as modulating brain-gut signaling pathways [7]. Almost all of this is preclinical; human evidence is limited to three small pilot studies [2].
Is BPC-157 a growth hormone?
No. BPC-157 is not a growth hormone. It is a synthetic fifteen-amino-acid peptide derived from a protein in gastric juice. There is a connection point that sometimes creates confusion: in tendon fibroblasts, BPC-157 has been reported to sensitize the growth-hormone receptor, which could amplify the body's own growth hormone signal [7]. But making a receptor more responsive is not the same as being growth hormone. BPC-157 is not growth hormone and does not replace it.
Does BPC-157 work immediately, and how long does it stay in the body?
The intact peptide clears from the bloodstream quickly. Pharmacokinetic work in rats and dogs found an elimination half-life under 30 minutes, with rapid breakdown into small fragments that re-enter normal amino-acid metabolism [3]. A short half-life means the peptide does not linger long after dosing. Whether any repair effect appears quickly is a separate question that the published animal data do not resolve on short timescales; healing studies are measured over days to weeks, not immediate time windows [6]. This site does not advise on dosing or timing.
Does BPC-157 damage the liver?
The available data do not show liver harm, but the data are very thin. In the 2025 first-in-human intravenous safety pilot, BPC-157 up to 20 mg in two healthy adults produced no measurable changes in hepatic, cardiac, renal, thyroid or glucose biomarkers and no adverse events [1]. That is reassuring, and it is two people in a safety pilot, not a liver-safety study. A 2025 review stresses that without long-term, large-sample human data the overall safety profile remains genuinely unknown [2]. Nothing here is medical advice.
What is TB-500, and what does the TB stand for?
"TB" refers to thymosin beta — specifically thymosin beta-4 (Tβ4), the natural protein TB-500 is derived from. TB-500 itself is a synthetic seven-amino-acid fragment, Ac-LKKTETQ, corresponding to the actin-binding region (residues 17-23) of that protein [12]. An important nuance: in commerce and anti-doping science, "TB-500" means the short fragment, but most published efficacy research uses the full-length Tβ4 protein, which is about five times larger [8]. The name points at a fragment while much of its reputation rests on the whole protein.
What is TB-500 used for in research?
In research, TB-500 (and, more often, full-length thymosin beta-4) is studied for tissue repair driven by actin regulation: cell migration, angiogenesis, reduced scarring and anti-inflammatory signaling, across models of dermal wounds, cornea, heart and CNS [10]. A human Phase 1 study of full-length Tβ4 in 40 volunteers assessed safety and pharmacokinetics rather than disease-specific efficacy [11], and a rat stroke study examined neurological recovery [9]. No completed controlled clinical trials of the TB-500 fragment itself exist for any indication [8].
Does TB-500 work for muscle tears and exercise recovery?
There is no controlled human evidence that the TB-500 fragment helps muscle tears or exercise recovery. The mechanistic rationale comes from thymosin beta-4's role in cell migration and tissue repair [10], but a 2026 Sports Medicine review of unapproved peptides for musculoskeletal injury concluded that favorable animal results have not been matched by rigorous human safety or efficacy data, and that these compounds operate largely outside regulatory oversight [8]. Notably, in a muscular-dystrophy mouse model, chronic Tβ4 increased regenerating fibers but did not improve muscle strength [10]. TB-500 is also WADA-prohibited [8].
What does GHK-Cu do, and how does it work?
GHK-Cu is a copper-carrying tripeptide that does two things simultaneously: it ferries copper into tissue and it signals repair. At very low concentrations it tells dermal fibroblasts to synthesize collagen, elastin, glycosaminoglycans and decorin, while rebalancing matrix-degrading enzymes against their inhibitors; the copper enables collagen cross-linking and provides antioxidant activity [16]. At the gene level it shifts expression of roughly 31.2% of human genes (at a 50%-or-greater change threshold) toward repair, DNA-repair and antioxidant programs [14]. Most of its documented human benefit is in topical skin applications [13].
Is GHK-Cu peptide really anti-aging?
There is real, if modest and mostly topical, human evidence for skin benefits. Topical GHK-Cu increased collagen production in about 70% of treated women, outperforming vitamin C (50%) and retinoic acid (40%) in the same comparison, and the literature documents placebo-controlled improvements in skin laxity, clarity, fine lines and wrinkle depth [16]. Two honest caveats: the widely quoted "~4,000 genes" claim is an extrapolation from a verified threshold of roughly 2,100 genes [14], and GHK-Cu penetrates intact skin poorly, limiting how much reaches the dermis without delivery aids [13]. Systemic "anti-aging" use is unproven.
What is the difference between GHK and GHK-Cu?
GHK is the bare tripeptide glycyl-histidyl-lysine; GHK-Cu is that same tripeptide chelated to a copper(II) ion. The distinction matters — copper coordination is required for most of GHK's reported bioactivities, so the form used in a given study is genuinely important, and the two are frequently conflated in secondary sources [16]. When research describes collagen stimulation, cross-linking and antioxidant effects, it is generally the copper complex (GHK-Cu) doing the work.
What is KPV peptide, and what is it used for?
KPV is a three-amino-acid peptide (Lys-Pro-Val) that is the C-terminal tail of the hormone alpha-MSH. In research it acts as an anti-inflammatory agent: it suppresses NF-kB and MAP-kinase signaling that drives inflammation and lowers pro-inflammatory cytokines [20], while lacking the pigment-producing effect of the full hormone [22]. Its most-studied use is in models of gut inflammation (colitis in mice), where it has reduced disease severity and accelerated mucosal healing [21][19]. There are no human clinical trials of KPV [20].
What is the Wolverine peptide blend?
Wolverine is a research-community blend pairing BPC-157 and TB-500 in a single co-formulated vial. It is not a single molecule. The rationale is that BPC-157 provides an angiogenic signal (new blood-vessel growth via VEGFR2) [4] while TB-500, via its thymosin beta-4 lineage, provides a cell-migration signal (actin regulation) [10] — two complementary repair mechanisms. No peer-reviewed study has tested the combination, so all "synergy" claims are extrapolations from the single-compound literature. Both components are WADA-prohibited [8].
What is BPC-157 and TB-500, and why are they combined?
BPC-157 is a 15-amino-acid peptide from gastric juice, studied for angiogenesis and gut/tendon repair [4][5]. TB-500 is a 7-amino-acid fragment of thymosin beta-4, studied for actin-based cell migration and wound healing [10]. They are combined in the Wolverine blend on the theory that hitting both blood-vessel supply and cell-migration simultaneously would be more effective than either alone. The theory is plausible and internally consistent — but no combination study exists that tests it. The 2026 Sports Medicine review [8] covers both compounds and makes clear that the human evidence for each is sparse; a combination study has yet to be done.
What is KLOW peptide?
KLOW is a four-peptide research blend co-formulating KPV, GHK-Cu, BPC-157 and TB-500. The name approximately abbreviates the four components. A common vial composition is GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg in an 80 mg lyophilized vial. The rationale assigns each peptide to a different step of tissue repair: inflammation suppression (KPV), matrix scaffolding (GHK-Cu), angiogenesis (BPC-157) and cell migration (TB-500). No controlled study has tested the combination.
What is KLOW peptide used for in research?
KLOW is discussed in research-use communities primarily in the context of tissue recovery — tendon, ligament and joint repair, with gut comfort and skin improvements also mentioned. The underlying research for each component touches tendon and muscle repair (BPC-157) [6], actin-biology and cell migration (TB-500) [10], skin matrix synthesis (GHK-Cu) [16], and gut-inflammation models (KPV) [20]. None of this research was conducted with the four-peptide blend; the "KLOW use" framing is a community extrapolation from single-compound studies.
Are there injection-site side effects with KLOW or Wolverine?
Community accounts for KLOW describe injection-site redness, swelling or itching as the most frequently reported downside — typically minor and short-lived. Mild initial fatigue, headache, light-headedness, flushing, and transient nausea are also mentioned occasionally. These reports come from uncontrolled, unverified use in research-community settings; dose and product identity are unknowable. They are anecdotal reports, not clinical findings, and this site does not recommend human use or validate any protocol [8].